Alabi Babatunde Adebola, Nku-Ekpang Okot-Asi, Lawal Sodiq Kolawole, Iwalewa Ezekiel Olugbenga, Omobowale Temidayo, Ajike Richard, Lawal Ridwan Abiodun
Department of Pharmacology and Therapeutics, Bowen University, Iwo, Nigeria.
Department of Pharmacy, Kampala International University in Tanzania, Dar es Salaam, Tanzania.
Front Pharmacol. 2024 Sep 10;15:1456903. doi: 10.3389/fphar.2024.1456903. eCollection 2024.
Ischemia-reperfusion injury (IRI) is unavoidable during kidney transplant and it is responsible for delayed or non-function after kidney transplantation. Cysteamine is the standard drug in the management of nephropathic cystinosis and its extra-renal complications. Thus, we designed this study to investigate its potential against renal reperfusion injury.
Significant elevation of HO MDA, and nitrite and reduced GPx, GSH, and protein thiol in the Ischemia-reperfusion injury rats was reversed by cysteamine (50 and 100 mg/kg). Serum MPO, TNF-α, IL-1β, creatinine, and AOPP were significantly elevated in IRI while rats treated with cysteamine revealed a significant decrease ( < 0.05) in the activities of these pro-inflammatory and renal injury markers.
Based on its activity against inflammation, apoptosis, and free radical-induced stress, cysteamine has great potential to be used as a kidney transplant pre-operative drug to prevent renal reperfusion injury.
肾移植过程中缺血再灌注损伤（IRI）不可避免，且是导致肾移植后延迟或无功能的原因。半胱胺是治疗肾病性胱氨酸病及其肾外并发症的标准药物。因此，我们设计了本研究以探究其抗肾再灌注损伤的潜力。
半胱胺（50和100mg/kg）可逆转缺血再灌注损伤大鼠中HO、MDA、亚硝酸盐的显著升高以及谷胱甘肽过氧化物酶（GPx）、谷胱甘肽（GSH）和蛋白质巯基的降低。IRI大鼠血清髓过氧化物酶（MPO）、肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）、肌酐和晚期氧化蛋白产物（AOPP）显著升高，而用半胱胺治疗的大鼠这些促炎和肾损伤标志物的活性显著降低（<0.05）。
基于其抗炎、抗凋亡和抗自由基诱导应激的活性，半胱胺极有潜力用作肾移植术前药物以预防肾再灌注损伤。
